TNFSF10 and gastric carcinoma: Although previously the expression levels of TRAIL were investigated in gastric carcinomas [37], to date there are no data available that analyzed the expression of the alternative TRAIL splice variants in malignant diseases such as gastric carcinomas (for better discrimination TRAIL is denoted in this article as TRAIL-α).